Melanoma/Skin Cancers

 
Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, et al.
The study authors conclude that Avelumab monotherapy led to a meaningful long-term overall survival in a subset of patients withMerkel cell carcinoma whose disease had progressed after chemotherapy. The authors state, that these results further support the role of avelumab as a standard-of-care treatment for patients withMerkel cell carcinoma. Clinical trial information: NCT02155647
 
 
Alexander M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.

The study authors conclude, that Pembrolizumab treatment after crossover yielded a 39% overall response rate in evaluable patients and an overall 3-yr progression-free disease rate of ̃32%. After rechallenge the efficacy was lower.Clinical trial information: NCT0236259

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

 
Kenneth F. Grossmann, Megan Othus, Sapna Pradyuman Patel, et al.
The study authors conclude, that Pembrolizumab improves relapse-free survival but not overall survival compared to high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10) in the adjuvant treatment of patients with high-risk resected melanoma. It is shown, that Pembrolizumab is a better tolerated adjuvant treatment regimen than HDI or Ipi10. Clinical trial information: NCT02506153
 
 
Rodabe Navroze Amaria, Michael A. Postow, Michael T. Tetzlaff, et al.
The study authors conclude, that neoadjuvant and adjuvant treatment with nivolumab and relatlimab (anti Lymphocyte Activation Gene-3 antibody) achieved high pathologic complete response and major pathologic response rates (MPR) with a favorable toxicity profile in the neoadjuvant and adjuvant settings. Patients with MPR were shown to have an improved outcome compared to non-MPR patients. Clinical trial information: NCT02519322
 
The study authors conclude, that 1st-line treatment with relatlimab + nivolumab as a fixed-dose combination (FDC) demonstrated a statistically significant PFS benefit compared to NIVO monotherapy in patients with advanced melanoma. The fixed-dose combination was well tolerated. The safety profile was manageable without unexpected safety signals. This first phase III study with a novel fixed-dose combination demonstrates a clinically meaningful benefit by a dual inhibition of the theLymphocyte-activation gene 3 and PD-1 pathways. Clinical trial information: NCT03470922
 
 
Ana Maria Arance, Luis de la Cruz-Merino, Teresa M. Petrella, et al. 
The study authors conclude, that the combination of lenvatinib and pembrolizumab continues to show clinically meaningful, durable responses in patients with advanced melanoma with confirmed progression on a prior PD-(L)1 inhibitor. This includes those patients with PD on anti–PD-1 + anti–CTLA-4 therapy regardless of primary or secondary resistance to prior anti–PD-(L)1 therapy. There were no new safety signals observed. The study data support lenvatinib plus pembrolizumab as a potential regimen for this study population. Clinical trial information: NCT03776136
 
 
James Larkin, Amod Sarnaik, Jason Alan Chesney, et al.
The study authors conclude, that one-time lifileucel treatment - an adoptive cell therapy using tumor-infiltrating lymphocytes - results in a 36.4%Objective response rate, and median duration of response (mDOR) was not reached at 28 mos of median study follow up. Duration of response is positively associated with primary resistance to prior anti-PD-1 therapy and with a shorter cumulative prior duration of anti-PD-1 therapy. The study demonstrates, that Lifileucel may offer a better clinical outcome when used earlier upon detection of progression on prior anti-PD-1 rather than retreatment with anti-PD-1 based regimens. Clinical trial information: NCT02360579
 
 
Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, et al.
The study authors demonstrate with this analysis of the longest follow-up (6.5-y ) from a phase 3 melanoma trial in the modern checkpoint inhibitor combination therapy and targeted therapy era durable improved outcomes with nivolumab plus ipilimumab (NIVO + IPI) and NIVO vs IPI in patients with advanced melanoma. Improvements were observed in OS, PFS, and ORR with NIVO + IPI over NIVO alone. Clinical trial information: NCT01844505
 
 
Reinhard Dummer, Keith Flaherty, Caroline Robert, et al.
The study authors report updated overall survival and duration of response results with encorafenib 450 mg QD + binimetinib 45 mg BID (COMBO450) that demonstrates continued long-term benefits in patients with BRAF V600-mutant melanoma. Clinical trial information: NCT01909453
 
 
Georgina V. Long, Victoria Atkinson, Serigne Lo, et al.
The study authors conclude, that nivolumab monotherapy and ipi+nivo are successful options in melanoma brain metastases. A durable response was observed in the majority of patients with ipi+nivo upfront. Clinical trial information: NCT02374242